The burden of progressive fibrotic interstitial lung disease across the UK

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Respir J
Asıl Yazarlar: Simpson, Thomas, Barratt, Shaney L., Beirne, Paul, Chaudhuri, Nazia, Crawshaw, Anjali, Crowley, Louise E., Fletcher, Sophie, Gibbons, Michael A., Hallchurch, Philippa, Horgan, Laura, Jakaityte, Ieva, Lewis, Thomas, McLellan, Tom, Myall, Katherine J., Miller, Ryan, Smith, David J.F., Stanel, Stefan, Thillai, Muhunthan, Thompson, Fiona, Wallis, Timothy, Wu, Zhe, Molyneaux, Philip L., West, Alex G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: European Respiratory Society 2021
Konular:
Agora
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264777/
https://ncbi.nlm.nih.gov/pubmed/33678609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00221-2021
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller